Acura Pharmaceuticals IncFind Ratings Reports
ACURA PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ACURA PHARMACEUTICALS INC has strong liquidity. Currently, the Quick Ratio is 1.78 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 60.93% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||0.26||0.09|
|Net Income ($mil)||-3.29||-2.66|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||6.78||10.92|
|Total Assets ($mil)||10.22||14.96|
|Total Debt ($mil)||6.79||9.05|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||94.16||28.57|
|Return on Assets||-100.14||-46.94|
|Return on Equity||-625.35||-167.63|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||11.83||9.84|
|Div / share||0.0||0.0|
|Book value / share||0.14||0.43|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||47376.0||40813.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.30 indicates a significant premium versus the S&P 500 average of 2.79 and a significant discount versus the industry average of 64.34. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ACURA PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.
|ACUR NM||Peers 27.27||ACUR NM||Peers 18.34|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ACUR's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ACUR's P/CF is negative making the measure meaningless.
|ACUR NM||Peers 14.26||ACUR NA||Peers 0.49|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ACUR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ACUR 7.30||Peers 64.34||ACUR -24.28||Peers -12.59|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ACUR is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ACUR is expected to significantly trail its peers on the basis of its earnings growth rate.
|ACUR 3.55||Peers 13.92||ACUR -41.98||Peers 5.28|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ACUR is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ACUR significantly trails its peers on the basis of sales growth